PloS one
Cure8 research brief
Why This Matters
People who have both IBD and type 2 diabetes are at increased cardiovascular risk; this study suggests GLP-1–based therapies may be associated with lower rates of several heart and thrombotic events in that group.
Who Should Pay Attention
Adults with IBD and coexisting type 2 diabetes, clinicians managing diabetes or IBD, and researchers studying cardiovascular risk or incretin therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a TriNetX retrospective observational study (matched cohorts) of adults with T2D and IBD between 2015–2024. The authors combined GLP-1 and dual GLP-1/GIP receptor agonists into one exposure group and report lower hazards for events including myocardial infarction, heart failure, ischemic stroke, atrial fibrillation, and venous thromboembolism.
The study is associational: it cannot prove causation, and the two drug classes were not compared against each other. The results are hypothesis-generating and may be affected by residual confounding despite propensity matching.
Clinicians and patients should view this as preliminary real-world evidence that merits further study rather than a definitive change in practice.
Keep In Mind
This is a retrospective observational analysis using an electronic health record–based research network. The exposure combined two drug classes and the design cannot establish causality; residual confounding is possible. The article provides an abstract-level summary rather than a full trial record.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPloS one
AuthorsMuhammad Ali Ibrahim Kazi, Syed Musa Mufarrih, Akanksha Sirohi +5 more
InstitutionDepartment of Internal Medicine, Anne Arundel Medical Center, Annapolis, Maryland, United States of America.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 24, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: The authors have declared that no competing interests exist.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Cardiovascular Risk in IBD Similar After Treatment With JAK vs TNF Inhibitors
People with IBD who need advanced therapies may worry about cardiovascular risks linked to some JAK inhibitors. This study suggests, in a real-world cohort with cardiovascular risk factors, short-term (1-year) MACE risk...
Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
Ustekinumab Has Better Cardiovascular Safety Than Vedolizumab in IBD Management
Older adults with IBD have higher cardiovascular risk; medication choice may affect cardiovascular outcomes. This study suggests ustekinumab users had fewer deaths and some cardiac events than vedolizumab users, which...